JP5793188B2 - 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６ - Google Patents

自己免疫疾患治療及び予防薬としてのｃｔｒｐ６ Download PDF

Info

Publication number
JP5793188B2
JP5793188B2 JP2013515089A JP2013515089A JP5793188B2 JP 5793188 B2 JP5793188 B2 JP 5793188B2 JP 2013515089 A JP2013515089 A JP 2013515089A JP 2013515089 A JP2013515089 A JP 2013515089A JP 5793188 B2 JP5793188 B2 JP 5793188B2
Authority
JP
Japan
Prior art keywords
ctrp6
disease
complement
mice
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013515089A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012157479A1 (ja
Inventor
洋一郎 岩倉
洋一郎 岩倉
正承 村山
正承 村山
晴道 石亀
晴道 石亀
角田　茂
茂 角田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Priority to JP2013515089A priority Critical patent/JP5793188B2/ja
Publication of JPWO2012157479A1 publication Critical patent/JPWO2012157479A1/ja
Application granted granted Critical
Publication of JP5793188B2 publication Critical patent/JP5793188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
JP2013515089A 2011-05-13 2012-05-09 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６ Active JP5793188B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013515089A JP5793188B2 (ja) 2011-05-13 2012-05-09 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161485746P 2011-05-13 2011-05-13
US61/485746 2011-05-13
JP2011219350 2011-10-03
JP2011219350 2011-10-03
JP2013515089A JP5793188B2 (ja) 2011-05-13 2012-05-09 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６
PCT/JP2012/061827 WO2012157479A1 (fr) 2011-05-13 2012-05-09 Ctrp6 qui peut être utilisée à titre d'agent thérapeutique et prophylactique pour les maladies auto-immunes

Publications (2)

Publication Number Publication Date
JPWO2012157479A1 JPWO2012157479A1 (ja) 2014-07-31
JP5793188B2 true JP5793188B2 (ja) 2015-10-14

Family

ID=47176809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515089A Active JP5793188B2 (ja) 2011-05-13 2012-05-09 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６

Country Status (4)

Country Link
US (1) US9175054B2 (fr)
EP (1) EP2708233B1 (fr)
JP (1) JP5793188B2 (fr)
WO (1) WO2012157479A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6551886B2 (ja) * 2013-11-15 2019-07-31 学校法人東京理科大学 自己免疫疾患の治療薬及び治療方法
WO2018124132A1 (fr) * 2016-12-26 2018-07-05 日本ビーシージー製造株式会社 Préparation d'émulsion huile dans eau contenant un composant de squelette à paroi cellulaire bactérienne
US20200397827A1 (en) * 2018-02-14 2020-12-24 Tokyo University Of Science Foundation Chondrocyte proliferation promoter, chondrocyte proliferation promotion method, screening method for chondrocyte proliferation promoters
CN111298121B (zh) * 2020-02-26 2022-02-18 嘉兴学院 Ctrp6基因缺失在抑制肿瘤生长中的应用
CN111778284B (zh) * 2020-06-24 2023-09-22 西安医学院 通过ctrp6介导的动脉粥样化动物模型及其建立方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530452A (ja) * 2004-03-10 2007-11-01 ペプジェン コーポレイション インターロイキン−τを用いる処置を最適化する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5037100A (en) * 1999-05-27 2000-12-18 Zymogenetics Inc. Adipocyte complement related protein homolog zacrp6
US20040248156A1 (en) 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
ES2387275T3 (es) 2003-05-15 2012-09-19 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
CN101018807A (zh) 2004-05-21 2007-08-15 赞科股份有限公司 免疫原性改变的C1q家族成员蛋白
US7385066B2 (en) 2005-03-16 2008-06-10 Janssen Pharmaceutica N.V. Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions
BRPI0708588A2 (pt) 2006-03-08 2011-06-07 Archemix Corp aptámeros de ligaçao ao complemento e agentes anti-c5 usados no tratamento de desordens oculares

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530452A (ja) * 2004-03-10 2007-11-01 ペプジェン コーポレイション インターロイキン−τを用いる処置を最適化する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014042344; ＫＩＭ，Ｍ．-Ｊ．　ｅｔ　ａｌ．: 'Ｃ１ｑＴＮＦ-ｒｅｌａｔｅｄ　ｐｒｏｔｅｉｎ-６　ｉｎｃｒｅａｓｅｓ　ｔｈｅ　ｅｘｐｒｅｓｓｉｏｎ　ｏｆｉｎｔｅｒｌｅｕｋｉｎ-１０　ｉｎ　ｍａｃｒｏｐｈａｇｅｓ' Ｍｏｌｅｃｕｌｅｓ　ａｎｄ　Ｃｅｌｌｓ Ｖｏｌ．３０，　Ｎｏ．１, 2010, ｐ．５９-６４ *
JPN6014042345; ＫＥＹＳＴＯＮＥ，Ｅ．　ｅｔ　ａｌ．: 'ＩＬ-１０　ａｓ　ａ　ｔｈｅｒａｐｅｕｔｉｃ　ｓｔｒａｔｅｇｙ　ｉｎ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆｒｈｅｕｍａｔｏｉｄ　ａｒｔｈｒｉｔｉｓ' Ｒｈｅｕｍａｔｉｃ　Ｄｉｓｅａｓｅ　Ｃｌｉｎｉｃｓ　ｏｆ　Ｎｏｒｔｈ　Ａｍｅｒｉｃａ Ｖｏｌ．２４，　Ｎｏ．３, 1998, ｐ．６２９-６３９ *
JPN7014002903; ＷＯＮＧ，　Ｇ．　Ｗ．　ｅｔ　ａｌ．: 'Ａ　ｆａｍｉｌｙ　ｏｆ　Ａｃｒｐ３０／ａｄｉｐｏｎｅｃｔｉｎ　ｓｔｒｕｃｔｕｒａｌ　ａｎｄｆｕｎｃｔｉｏｎａｌ　ｐａｒａｌｏｇｓ' Ｐｒｏｃ　Ｎａｔｌ　Ａｃａｄ　Ｓｃｉ　ＵＳＡ Ｖｏｌ．１０１，　Ｎｏ．２８, 2004, ｐ．１０３０２-１０３０７ *

Also Published As

Publication number Publication date
EP2708233A4 (fr) 2015-01-07
EP2708233B1 (fr) 2018-06-27
EP2708233A1 (fr) 2014-03-19
WO2012157479A1 (fr) 2012-11-22
JPWO2012157479A1 (ja) 2014-07-31
US9175054B2 (en) 2015-11-03
US20140194343A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
JP6620829B2 (ja) 認知症治療剤又は予防剤
JP5793188B2 (ja) 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６
Murayama et al. CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis
Long et al. Gob-5 contributes to goblet cell hyperplasia and modulates pulmonary tissue inflammation
JP6914193B2 (ja) Ｂｄｎｆを含む融合蛋白質
JP2016169208A (ja) Ｔｒｅｍ様転写物１（ｔｌｔ−１）から誘導された阻害性ペプチドおよびその使用
KR20210031868A (ko) Ditra 질환의 비인간 동물 모델 및 이의 용도
Michels et al. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
JP2022520862A (ja) 新規組換えジアミンオキシダーゼおよび過剰ヒスタミンによって特徴づけられる疾患の治療のためのその使用
WO2022037679A1 (fr) Utilisation d'une voie de signal d'interféron de type mcm8-cgas-sting-i comme cible de maladie
US8299097B2 (en) Methods for treating inflammatory disorders
US20120122107A1 (en) Homeostatic multidomain protein, and uses for it
US20220104468A1 (en) Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
JP2023521867A (ja) 改変インターロイキン２２ポリペプチド及びその使用
WO2014018079A1 (fr) Procédé pour traiter des troubles d'hyperglycémie au moyen d'apolipoprotéine aiv
CA3146031A1 (fr) Inducteur immunitaire et composition pharmaceutique pour la prevention ou le traitement de maladies liees au vieillissement
WO2016201528A1 (fr) Traitement d'une inflammation et/ou d'un cancer
US20150252074A1 (en) Antagonist for (Pro)Renin Receptor for the Treatment of Hypertension and Diabetes
JP2007022993A (ja) アレルギー性喘息の治療薬
US9512196B2 (en) Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
CN110769847A (zh) 治疗肺高压的组合物和方法
JP5884105B2 (ja) 酸化ｌｄｌ阻害剤
JP2015047157A (ja) 疼痛発症モデル動物および疼痛治療薬
JP6488376B2 (ja) 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬
US20220009987A9 (en) Human resistin compositions and methods of treating tlr4-mediated disease and infection

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150807

R150 Certificate of patent or registration of utility model

Ref document number: 5793188

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250